{
    "name": "lusutrombopag",
    "comment": "Rx",
    "other_names": [
        "Mulpleta"
    ],
    "classes": [
        "Thrombopoietic Agents"
    ],
    "source": "https://reference.medscape.com/drug/mulpleta-lusutrombopag-1000244",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to inform a drug-associated risk",
            "There is no information on the presence of lusutrombopag in human milk, the effects on the breastfed child, and the effects on milk production",
            "Drug was present in the milk of lactating rats",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, oral administration of lusutrombopag to pregnant rats during organogenesis and the lactation period resulted in adverse developmental outcomes",
                    "These finding were observed at exposures based on AUC that were substantially higher than the AUC observed in patients (~89 times) at the recommended clinical dose of 3 mg qDay; advise pregnant women of the potential risk to a fetus"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Lactating women should interrupt breastfeeding and pump and discard breast milk during treatment and for 28 days after the last dose in order to minimize exposure to a breastfed child"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information on the presence of lusutrombopag in human milk, the effects on the breastfed child, and the effects on milk production",
            "Drug was present in the milk of lactating rats",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Thrombotic or thromboembolic complications",
                    "description": [
                        "Thrombopoietin (TPO) receptor agonists, such as lusutrombopag, have been associated with thrombotic and thromboembolic complications (eg, portal vein thrombosis) in patients with chronic liver disease",
                        "Consider the potential increased thrombotic risk when administering drug to patients with known risk factors for thromboembolism (eg, genetic prothrombotic conditions [factor V Leiden, prothrombin 20210A, antithrombin deficiency, or protein C or S deficiency])",
                        "In patients with ongoing or prior thrombosis or absence of hepatopetal blood flow, use lusutrombopag if the potential benefit justifies the potential risk",
                        "Should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "5"
        },
        {
            "name": "Portal vein thrombosis",
            "percent": "1"
        }
    ]
}